GSA Capital Partners LLP Has $1.10 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS)

GSA Capital Partners LLP boosted its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 79.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 66,402 shares of the company's stock after purchasing an additional 29,496 shares during the period. GSA Capital Partners LLP owned 0.07% of NewAmsterdam Pharma worth $1,102,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in NAMS. Banque Cantonale Vaudoise acquired a new position in NewAmsterdam Pharma during the second quarter valued at $38,000. Rosalind Advisors Inc. purchased a new stake in shares of NewAmsterdam Pharma in the second quarter worth approximately $194,000. Wolverine Asset Management LLC lifted its position in shares of NewAmsterdam Pharma by 117.7% in the second quarter. Wolverine Asset Management LLC now owns 15,524 shares of the company's stock worth $298,000 after purchasing an additional 8,394 shares in the last quarter. Sei Investments Co. grew its position in NewAmsterdam Pharma by 49.1% during the second quarter. Sei Investments Co. now owns 24,561 shares of the company's stock valued at $472,000 after purchasing an additional 8,087 shares in the last quarter. Finally, Lisanti Capital Growth LLC acquired a new position in NewAmsterdam Pharma in the 3rd quarter valued at approximately $700,000. 89.89% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 45,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total transaction of $707,400.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 19.50% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on NAMS shares. Royal Bank of Canada restated an "outperform" rating and set a $31.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Needham & Company LLC restated a "buy" rating and issued a $36.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, November 7th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, NewAmsterdam Pharma currently has a consensus rating of "Buy" and an average price target of $33.80.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS traded down $0.07 during trading on Friday, hitting $24.90. 891,907 shares of the stock were exchanged, compared to its average volume of 270,394. NewAmsterdam Pharma has a 1-year low of $8.90 and a 1-year high of $26.35. The company's fifty day simple moving average is $18.35 and its 200-day simple moving average is $18.61.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.